MEA Lipids Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Middle East and Africa lipids market is projected to register a substantial CAGR of 7.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Lipids Market, By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and others), Source (Eggyolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries, and Others), Distribution Channel (Direct Tender, Retail Sales and, Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of Middle East and Africa lipids market are:

Increasing manufacturing capacity globally

Increased consumption of fast food

Market Players:

The major companies which are dealing in the Middle East and Africa lipids market are listed below:

Alnylam Pharmaceutical, Inc.,

Croda International Plc.

Moderna Inc.

BioNTech SE.,

Pfizer Inc.

Evonik Industries AG

Lipoid GmbH

Matreya LLC

VAV Life Sciences Pvt Ltd.

Curia Middle East and Africa Inc.

Cargill, Incorporated

Gattefosse

CD Bioparticles

Merck KGaA

Cayman Chemical

1 INTRODUCTION 44

1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LIPIDS MARKET 44
1.4 LIMITATIONS 46
1.5 MARKETS COVERED 46

2 MARKET SEGMENTATION 50

2.1 MARKETS COVERED 50
2.2 GEOGRAPHICAL SCOPE 51
2.3 YEARS CONSIDERED FOR THE STUDY 52
2.4 CURRENCY AND PRICING 52
2.5 DBMR TRIPOD DATA VALIDATION MODEL 53
2.6 MULTIVARIATE MODELLING 56
2.7 TYPE LIFELINE CURVE 56
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 57
2.9 DBMR MARKET POSITION GRID 58
2.10 MARKET END USER COVERAGE GRID 59
2.11 VENDOR SHARE ANALYSIS 60
2.12 SECONDARY SOURCES 61
2.13 ASSUMPTIONS 61

3 EXECUTIVE SUMMARY 62

4 PREMIUM INSIGHTS 65

4.1 PESTEL ANALYSIS 66
4.2 PORTER'S FIVE FORCES 67
4.3 MERGER AND ACQUISITION, MIDDLE EAST & AFRICA LIPIDS MARKET 68
4.4 PATENT ANALYSIS, MIDDLE EAST & AFRICA LIPIDS MARKET 69
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 70
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 71
4.7 KEY PRICING STRATEGIES 72
4.8 KEY PATIENT ENROLLMENT STRATEGIES 73
4.9 PRICE ANALYSIS, MIDDLE EAST & AFRICA LIPIDS MARKET 74
4.10 MIDDLE EAST & AFRICA LIPIDS MARKET, CLINICAL TRIALS 76
4.11 MIDDLE EAST & AFRICA LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE 77
4.12 MIDDLE EAST & AFRICA LIPIDS MARKET, PIPELINE ANALYSIS 78
4.13 PHASE I CANDIDATES 78
4.14 PHASE I/II CANDIDATES 79
4.15 PHASE II CANDIDATES 80
4.16 PHASE III CANDIDATES 81

5 MIDDLE EAST & AFRICA LIPIDS MARKET, REGULATORY FRAMEWORK 82

5.1 REGULATION IN THE U.S.: 82
5.2 REGULATION IN EUROPE: 83

6 MARKET OVERVIEW 84

6.1 DRIVERS 86
- 6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES 86
- 6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY 86
- 6.1.3 INCREASE IN DRUG DEVELOPMENT 87
6.2 RESTRAINTS 87
- 6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS 87
- 6.2.2 STRICT GOVERNMENT REGULATIONS 88
6.3 OPPORTUNITIES 89
- 6.3.1 RISE IN HEALTHCARE EXPENDITURE 89
- 6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 89
6.4 CHALLENGES 90
- 6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION 90
- 6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES 90

7 MIDDLE EAST & AFRICA LIPIDS MARKET, BY TYPE 91

7.1 OVERVIEW 92
7.2 NATURAL LIPID 95
- 7.2.1 UNSATURATED PHOSPHOLIPID 95
- 7.2.2 HYDROGENATED PHOSPHOLIPID 96
- 7.2.3 SPHINGOMYELIN 96
- 7.2.4 GLYCEROLPHOSPHOCHOLINE 96
7.3 SYNTHETIC LIPID 96
- 7.3.1 PEGYLATED PHOSPHOLIPIDS 97
- 7.3.2 PHOSPHATIDYLSERINE 97
- 7.3.3 PHOSPHATIDYGLYCEROLS 97
- 7.3.4 PHOSPHATIDYLETHANOLAMINE 97
- 7.3.5 PHOSPHATIDYLCHOLINE 97
- 7.3.6 PHOSPHATIDIC ACIDS 97

8 MIDDLE EAST & AFRICA LIPIDS MARKET, BY LIPID SYSTEMS 98

8.1 OVERVIEW 99
8.2 BIOACTIVE LIPIDS 102
- 8.2.1 PLANT LIPIDS 103
- 8.2.2 LIPID ACTIVATORS 103
- 8.2.3 LIPID INHIBITORS 103
- 8.2.4 AGONISTS 103
- 8.2.5 BIOACTIVE CERAMIDES 103
- 8.2.6 ACYL CARNITINE LIPIDS 103
- 8.2.7 ENDOCANNABINOIDS 104
- 8.2.8 LIPO-NUCLEOTIDES 104
- 8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL 104
- 8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP) 104
8.3 POLYMERIZABLE LIPIDS 104
- 8.3.1 FUNCTIONAL PEG LIPIDS 105
- 8.3.2 MPEG STEROLS 105
- 8.3.3 MPEG CERAMIDES 105
- 8.3.4 MPEG PHOSPHOLIPIDS 105
- 8.3.5 MPEG GLYCERIDES 105
8.4 FLUORESCENT LIPIDS 106
- 8.4.1 FLUORESCENT SPHINGOLIPIDS 107
- 8.4.2 FLUORESCENT GLYCEROLIPIDS 107
- 8.4.3 FLUORESCENT PEG LIPIDS 107
- 8.4.4 FLUORESCENT PHOSPHOLIPIDS 107
- 8.4.5 FLUORESCENT STEROLS 107
- 8.4.6 OTHERS 107
8.5 BACTERIAL LIPIDS 108
- 8.5.1 MYCOLIC LIPIDS 109
- 8.5.2 N-ACYLHOMOSERINE LIPIDS 109
- 8.5.3 BRANCHED LIPIDS 109
- 8.5.4 CYCLOPROPYL LIPIDS 109
8.6 NEUTRAL LIPIDS 109
- 8.6.1 PRENOLS 110
- 8.6.2 VERY LONG CHAIN FATTY ACIDS 110
- 8.6.3 GLYCERIDES 110
- 8.6.4 EICSANOIDS 110
- 8.6.5 OXYGENATED FATTY ACIDS 110
- 8.6.6 GLYCOSYLATED DIACYL GLYCEROLS 110
- 8.6.7 PROSTAGLANDINS 110
8.7 HEADGROUP MODIFIED LIPIDS 111
- 8.7.1 FUNCTIONAL LIPIDS 112
- 8.7.2 ANTIGENIC LIPIDS 112
- 8.7.3 GLYCOSYLATED LIPIDS 112
- 8.7.4 CHELATORS 112
- 8.7.5 ADHESIVE LIPIDS 112
- 8.7.6 SNAP-TAG REACTING LIPIDS 112
- 8.7.7 ALKYL PHOSPHATES 112
8.8 OTHERS 113

9 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DELIVERY SYSTEMS 114

9.1 OVERVIEW 115
9.2 LIPOSOMES 118
- 9.2.1 LIPOSOMES FOR DNA/RNA 119
  - 9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY 119
  - 9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY 119
  - 9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY 119
  - 9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY 119
  - 9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY 120
  - 9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY 120
- 9.2.2 REACTIVE LIPOSOMES 120
  - 9.2.2.1 SUCCINYL LIPOSOMES 120
  - 9.2.2.2 DBCO LIPOSOMES 120
  - 9.2.2.3 BIOTINYLATED LIPOSOMES 121
  - 9.2.2.4 CARBOXYLIC ACID LIPOSOMES 121
  - 9.2.2.5 AMINE LIPOSOMES 121
  - 9.2.2.6 CYANUR LIPOSOMES 121
  - 9.2.2.7 AZIDE LIPOSOMES 121
  - 9.2.2.8 FOLATE LIPOSOMES 121
  - 9.2.2.9 DODECANYL LIPOSOMES 121
  - 9.2.2.10 NI REACTIVE LIPOSOMES 121
  - 9.2.2.11 PDP LIPOSOMES 121
  - 9.2.2.12 GLUTARYL LIPOSOMES 121
  - 9.2.2.13 OTHERS 121
- 9.2.3 DRUG LOADED LIPOSOMES 122
- 9.2.4 PLAIN LIPOSOMES 122
  - 9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES 122
  - 9.2.4.2 DOTAP LIPOSOMES 122
  - 9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES 122
  - 9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES 122
  - 9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES 122
  - 9.2.4.6 OTHERS 123
9.3 SOLID LIPID NANOPARTICLES 123
9.4 NANOSTRUCTURES LIPID CARRIER 124
9.5 TRANSFEROSOMES 125
9.6 NIOSOMES 126
9.7 OTHERS 127

10 MIDDLE EAST & AFRICA LIPIDS MARKET, BY SOURCE 128

10.1 OVERVIEW 129
10.2 PURIFIED FATTY ACIDS 132
10.3 PURIFIED OILS 133
10.4 EGG YOLK 134
10.5 SOYABEAN 135
10.6 NON-GMO SOYABEAN 136
10.7 OTHERS 137

11 MIDDLE EAST & AFRICA LIPIDS MARKET, BY END USER 138

11.1 OVERVIEW 139
11.2 PHARMACEUTICAL INDUSTRIES 142
11.3 BIOTECHNOLOGY INDUSTRIES 143
11.4 COSMETIC INDUSTRIES 144
11.5 ACADEMIC AND RESEARCH INSTITUTES 144
11.6 OTHERS 145

12 MIDDLE EAST & AFRICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL 146

12.1 OVERVIEW 147
12.2 DIRECT TENDER 150
12.3 RETAIL SALES 151
12.4 OTHERS 152

13 MIDDLE EAST & AFRICA LIPIDS MARKET, BY REGION 153

13.1 MIDDLE EAST AND AFRICA 154
- 13.1.1 SOUTH AFRICA 166
- 13.1.2 SAUDI ARABIA 173
- 13.1.3 U.A.E. 180
- 13.1.4 EGYPT 187
- 13.1.5 ISRAEL 194
- 13.1.6 REST OF MIDDLE EAST AND AFRICA 201

14 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY LANDSCAPE 202

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 202

15 SWOT ANALYSIS 203

16 COMPANY PROFILE 204

16.1 BIONTECH SE. 204
- 16.1.1 COMPANY SNAPSHOT 204
- 16.1.2 REVENUE ANALYSIS 205
- 16.1.3 COMPANY SHARE ANALYSIS 205
- 16.1.4 PRODUCT PORTFOLIO 205
- 16.1.5 RECENT DEVELOPMENT 206
16.2 MODERNA, INC. 207
- 16.2.1 COMPANY SNAPSHOT 207
- 16.2.2 REVENUE ANALYSIS 207
- 16.2.3 COMPANY SHARE ANALYSIS 208
- 16.2.4 PRODUCT PORTFOLIO 208
- 16.2.5 RECENT DEVELOPMENTS 208
16.3 PFIZER INC. 209
- 16.3.1 COMPANY SNAPSHOT 209
- 16.3.2 REVENUE ANALYSIS 209
- 16.3.3 COMPANY SHARE ANALYSIS 210
- 16.3.4 PRODUCT PORTFOLIO 210
- 16.3.5 RECENT DEVELOPMENTS 210
16.4 CARGILL, INCORPORATED. 211
- 16.4.1 COMPANY SNAPSHOT 211
- 16.4.2 COMPANY SHARE ANALYSIS 211
- 16.4.3 PRODUCT PORTFOLIO 211
- 16.4.4 RECENT DEVELOPMENTS 211
16.5 KERRY. 212
- 16.5.1 COMPANY SNAPSHOT 212
- 16.5.2 COMPANY SHARE ANALYSIS 212
- 16.5.3 PRODUCT PORTFOLIO 213
- 16.5.4 RECENT DEVELOPMENTS 213
16.6 ABITEC 214
- 16.6.1 COMPANY SNAPSHOT 214
- 16.6.2 PRODUCT PORTFOLIO 214
- 16.6.3 RECENT DEVELOPMENTS 214
16.7 ADMSIO 216
- 16.7.1 COMPANY SNAPSHOT 216
- 16.7.2 PRODUCT PORTFOLIO 216
- 16.7.3 RECENT DEVELOPMENTS 216
16.8 ALNYLAM PHARMACEUTICALS, INC. 217
- 16.8.1 COMPANY SNAPSHOT 217
- 16.8.2 REVENUE ANALYSIS 217
- 16.8.3 PRODUCT PORTFOLIO 218
- 16.8.4 RECENT DEVELOPMENT 218
16.9 BASF SE 219
- 16.9.1 COMPANY SNAPSHOT 219
- 16.9.2 REVENUE ANALYSIS 220
- 16.9.3 PRODUCT PORTFOLIO 220
- 16.9.4 RECENT DEVELOPMENTS 220
16.10 CAYMAN CHEMICAL 221
- 16.10.1 COMPANY SNAPSHOT 221
- 16.10.2 PRODUCT PORTFOLIO 221
- 16.10.3 RECENT DEVELOPMENTS 221
16.11 CD BIOPARTCLES. 222
- 16.11.1 COMPANY SNAPSHOT 222
- 16.11.2 PRODUCT PORTFOLIO 222
- 16.11.3 RECENT DEVELOPMENTS 222
16.12 CHEMI S.P.A. 223
- 16.12.1 COMPANY SNAPSHOT 223
- 16.12.2 PRODUCT PORTFOLIO 223
- 16.12.3 RECENT DEVELOPMENTS 223
16.13 CORDENPHARMA INTERNATIONAL 224
- 16.13.1 COMPANY SNAPSHOT 224
- 16.13.2 PRODUCT PORTFOLIO 224
- 16.13.3 RECENT DEVELOPMENTS 224
16.14 CRODA INTERNATIONAL PLC. 226
- 16.14.1 COMPANY SNAPSHOT 226
- 16.14.2 PRODUCT PORTFOLIO 226
- 16.14.3 RECENT DEVELOPMENTS 226

16.15 CURIA MIDDLE EAST & AFRICA, INC. 227
- 16.15.1 COMPANY SNAPSHOT 227
- 16.15.2 PRODUCT PORTFOLIO 227
- 16.15.3 RECENT DEVELOPMENT 227
16.16 DSM 229
- 16.16.1 COMPANY SNAPSHOT 229
- 16.16.2 PRODUCT PORTFOLIO 229
- 16.16.3 RECENT DEVELOPMENTS 229
16.17 EVONIK INDUSTRIES AG 230
- 16.17.1 COMPANY SNAPSHOT 230
- 16.17.2 PRODUCT PORTFOLIO 230
- 16.17.3 RECENT DEVELOPMENTS 230
16.18 GATTEFOSSE 232
- 16.18.1 COMPANY SNAPSHOT 232
- 16.18.2 PRODUCT PORTFOLIO 232
- 16.18.3 RECENT DEVELOPMENTS 232
16.19 LIPOID GMBH 233
- 16.19.1 COMPANY SNAPSHOT 233
- 16.19.2 PRODUCT PORTFOLIO 233
- 16.19.3 RECENT DEVELOPMENT 234
16.20 MATREYA, LLC 235
- 16.20.1 COMPANY SNAPSHOT 235
- 16.20.2 PRODUCT PORTFOLIO 235
- 16.20.3 RECENT DEVELOPMENTS 235
16.21 MERCK KGAA 236
- 16.21.1 COMPANY SNAPSHOT 236
- 16.21.2 PRODUCT PORTFOLIO 236
- 16.21.3 RECENT DEVELOPMENTS 236
16.22 NOF EUROPE GMBH 237
- 16.22.1 COMPANY SNAPSHOT 237
- 16.22.2 PRODUCT PORTFOLIO 237
- 16.22.3 RECENT DEVELOPMENTS 237
16.23 STEPAN COMPANY 238
- 16.23.1 COMPANY SNAPSHOT 238
- 16.23.2 PRODUCT PORTFOLIO 238
- 16.23.3 RECENT DEVELOPMENTS 238
16.24 TOKYO CHEMICAL INDUSTRY CO., LTD. 240
- 16.24.1 COMPANY SNAPSHOT 240
- 16.24.2 PRODUCT PORTFOLIO 240
- 16.24.3 RECENT DEVELOPMENTS 240
16.25 VAV LIFE SCIENCES PVT LTD 241
- 16.25.1 COMPANY SNAPSHOT 241
- 16.25.2 PRODUCT PORTFOLIO 241
- 16.25.3 RECENT DEVELOPMENTS 241

17 QUESTIONNAIRE 242

18 RELATED REPORTS 246

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA LIPIDS MARKET: SEGMENTATION 27
FIGURE 2 MIDDLE EAST & AFRICA LIPIDS MARKET: DATA TRIANGULATION 30
FIGURE 3 MIDDLE EAST & AFRICA LIPIDS MARKET: DROC ANALYSIS 31
FIGURE 4 MIDDLE EAST & AFRICA LIPIDS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 32
FIGURE 5 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY RESEARCH ANALYSIS 32
FIGURE 6 MIDDLE EAST & AFRICA LIPIDS MARKET: INTERVIEW DEMOGRAPHICS 34
FIGURE 7 MIDDLE EAST & AFRICA LIPIDS MARKET: DBMR MARKET POSITION GRID 35
FIGURE 8 MIDDLE EAST & AFRICA LIPIDS MARKET: MARKET END USER COVERAGE GRID 36
FIGURE 9 MIDDLE EAST & AFRICA LIPIDS MARKET: VENDOR SHARE ANALYSIS 37
FIGURE 10 MIDDLE EAST & AFRICA LIPIDS MARKET: SEGMENTATION 41
FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 42
FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LIPIDS MARKET IN 2023 & 2030 42
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LIPIDS MARKET 62
FIGURE 14 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, 2022 69
FIGURE 15 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION) 70
FIGURE 16 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, CAGR (2023-2030) 70
FIGURE 17 MIDDLE EAST & AFRICA LIPIDS MARKET: BY TYPE, LIFELINE CURVE 71
FIGURE 18 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, 2022 76
FIGURE 19 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION) 77
FIGURE 20 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030) 77
FIGURE 21 MIDDLE EAST & AFRICA LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE 78
FIGURE 22 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022 92
FIGURE 23 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION) 93
FIGURE 24 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030) 93
FIGURE 25 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE 94
FIGURE 26 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, 2022 106
FIGURE 27 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION) 107
FIGURE 28 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, CAGR (2023-2030) 107
FIGURE 29 MIDDLE EAST & AFRICA LIPIDS MARKET: BY SOURCE, LIFELINE CURVE 108
FIGURE 30 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, 2022 116
FIGURE 31 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION) 117
FIGURE 32 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, CAGR (2023-2030) 117
FIGURE 33 MIDDLE EAST & AFRICA LIPIDS MARKET: BY END USER, LIFELINE CURVE 118
FIGURE 34 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022 124
FIGURE 35 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 125
FIGURE 36 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 125
FIGURE 37 MIDDLE EAST & AFRICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 126
FIGURE 38 MIDDLE EAST AND AFRICA LIPIDS MARKET: SNAPSHOT (2022) 132
FIGURE 39 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022) 134
FIGURE 40 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2023 & 2030) 134
FIGURE 41 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022 & 2030) 135
FIGURE 42 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY TYPE (2023 & 2030) 135
FIGURE 43 MIDDLE EAST & AFRICA LIPIDS MARKET: COMPANY SHARE 2022 (%) 179